Literature DB >> 18566991

Joint effects of inflammation and androgen metabolism on prostate cancer severity.

Timothy R Rebbeck1, Hanna Rennert, Amy H Walker, Saarene Panossian, Teo Tran, Kyle Walker, Elaine Spangler, Margerie Patacsil-Coomes, Rajeev Sachdeva, Alan J Wein, S Bruce Malkowicz, Charnita Zeigler-Johnson.   

Abstract

Multiple pathways of prostate carcinogenesis have been proposed, including those involving androgen metabolism and inflammation. These pathways are not independent, and may act together in prostate cancer etiology: androgens promote both inflammatory processes and serve as mitogens in prostate tumor growth. To explore the possible joint effects of these pathways in prostate cancer severity, we studied 1,090 Caucasian prostate cancer cases to evaluate whether tumor severity is influenced by a history of benign prostatic hyperplasia (BPH) interacting with genotypes involved in inflammation or androgen metabolism including MSR1, RNASEL, AR, CYP3A4, CYP3A43, CYP3A5 and SRD5A2. We observed a statistically significant interaction between a number of genotypes and BPH. After considering the potential for false positive associations, the only remaining significant associations involved CYP3A43 P340A genotypes and history of BPH on both Gleason grade (interaction p-value = 0.026) and tumor stage (interaction p-value = 0.017). These results suggest that androgen metabolism may act in concert with inflammatory phenotypes such as BPH in determining prostate cancer severity. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566991      PMCID: PMC2700293          DOI: 10.1002/ijc.23687

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer.

Authors:  Charnita Zeigler-Johnson; Tara Friebel; Amy H Walker; Yiting Wang; Elaine Spangler; Saarene Panossian; Margerie Patacsil; Richard Aplenc; Alan J Wein; S Bruce Malkowicz; Timothy R Rebbeck
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

Review 2.  Regulation of prostate growth.

Authors:  P Davies; C L Eaton
Journal:  J Endocrinol       Date:  1991-10       Impact factor: 4.286

3.  Androgens regulate the immune/inflammatory response and cell survival pathways in rat ventral prostate epithelial cells.

Authors:  A J Asirvatham; M Schmidt; B Gao; J Chaudhary
Journal:  Endocrinology       Date:  2005-09-29       Impact factor: 4.736

4.  Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men.

Authors:  Hanna Rennert; Charnita M Zeigler-Johnson; Kathakali Addya; Matthew J Finley; Amy H Walker; Elaine Spangler; Debra G B Leonard; Alan Wein; S Bruce Malkowicz; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-04       Impact factor: 4.254

5.  Interaction between the androgen receptor and RNase L mediates a cross-talk between the interferon and androgen signaling pathways.

Authors:  David J Bettoun; Angela Scafonas; Su Jane Rutledge; Paul Hodor; Oliver Chen; Carlo Gambone; Robert Vogel; Sheila McElwee-Witmer; Chang Bai; Leonard Freedman; Azriel Schmidt
Journal:  J Biol Chem       Date:  2005-09-14       Impact factor: 5.157

6.  CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians.

Authors:  Angie Stone; Luke D Ratnasinghe; Ginny L Emerson; Rama Modali; Terri Lehman; Gail Runnells; Alindria Carroll; Weleetka Carter; Samuel Barnhart; Al A Rasheed; Graham Greene; Don E Johnson; Christine B Ambrosone; Fred F Kadlubar; Nicholas P Lang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-05       Impact factor: 4.254

Review 7.  Prostate carcinogenesis and inflammation: emerging insights.

Authors:  Ganesh S Palapattu; Siobhan Sutcliffe; Patrick J Bastian; Elizabeth A Platz; Angelo M De Marzo; William B Isaacs; William G Nelson
Journal:  Carcinogenesis       Date:  2004-10-21       Impact factor: 4.944

Review 8.  Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity.

Authors:  M Cutolo; A Sulli; S Capellino; B Villaggio; P Montagna; B Seriolo; R H Straub
Journal:  Lupus       Date:  2004       Impact factor: 2.911

9.  Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats.

Authors:  D L McCormick; K V Rao; L Dooley; V E Steele; R A Lubet; G J Kelloff; M C Bosland
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

Review 10.  Dietary influences on endocrine-inflammatory interactions in prostate cancer development.

Authors:  Emily Ho; Thomas W-M Boileau; Tammy M Bray
Journal:  Arch Biochem Biophys       Date:  2004-08-01       Impact factor: 4.013

View more
  13 in total

1.  The viral theory of schizophrenia revisited: abnormal placental gene expression and structural changes with lack of evidence for H1N1 viral presence in placentae of infected mice or brains of exposed offspring.

Authors:  S Hossein Fatemi; Timothy D Folsom; Robert J Rooney; Susumu Mori; Tess E Kornfield; Teri J Reutiman; Rachel E Kneeland; Stephanie B Liesch; Kegang Hua; John Hsu; Divyen H Patel
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

2.  Identification of genetic risk associated with prostate cancer using ancestry informative markers.

Authors:  L J Ricks-Santi; V Apprey; T Mason; B Wilson; M Abbas; W Hernandez; S Hooker; M Doura; G Bonney; G Dunston; R Kittles; C Ahaghotu
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-07-17       Impact factor: 5.554

Review 3.  Genetic variation in CYP3A43 is associated with response to antipsychotic medication.

Authors:  Eva J Brandl; Nabilah I Chowdhury; Arun K Tiwari; Tristram A P Lett; Herbert Y Meltzer; James L Kennedy; Daniel J Müller
Journal:  J Neural Transm (Vienna)       Date:  2014-08-24       Impact factor: 3.575

4.  Mutational landscape of candidate genes in familial prostate cancer.

Authors:  Anna M Johnson; Kimberly A Zuhlke; Chris Plotts; Shannon K McDonnell; Sumit Middha; Shaun M Riska; Daniel J Schaid; Stephen N Thibodeau; Julie A Douglas; Kathleen A Cooney
Journal:  Prostate       Date:  2014-08-11       Impact factor: 4.104

5.  Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures.

Authors:  Shannon M Lynch; Nandita Mitra; Krithika Ravichandran; Jonathan Mitchell; Elaine Spangler; Wenting Zhou; Electra D Paskett; Sarah Gehlert; Cecilia DeGraffinreid; Raymond Stowe; Tamara Dubowitz; Harold Riethman; Charles C Branas; M K Peek; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-04       Impact factor: 4.254

6.  The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth.

Authors:  Rajendra Kumar Singh; Bal L Lokeshwar
Journal:  Cancer Res       Date:  2011-03-11       Impact factor: 12.701

7.  The type 1 diabetes - HLA susceptibility interactome--identification of HLA genotype-specific disease genes for type 1 diabetes.

Authors:  Caroline Brorsson; Niclas Tue Hansen; Regine Bergholdt; Søren Brunak; Flemming Pociot
Journal:  PLoS One       Date:  2010-03-05       Impact factor: 3.240

Review 8.  Genetic variation: effect on prostate cancer.

Authors:  Tristan M Sissung; Douglas K Price; Marzia Del Re; Ariel M Ley; Elisa Giovannetti; William D Figg; Romano Danesi
Journal:  Biochim Biophys Acta       Date:  2014-09-06

9.  Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States.

Authors:  Megan Dann Fesinmeyer; Roman Gulati; Steve Zeliadt; Noel Weiss; Alan R Kristal; Ruth Etzioni
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-03       Impact factor: 4.254

Review 10.  [Influence of obesity on urological malignancies].

Authors:  H Eggers; M A Kuczyk; A J Schrader; S Steffens
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.